SomnusNooze e-newsletter
News, stories and updates from the world of sleep
SomnusNooze Author: Hypersomnia Foundation
What Does One SOREMP Mean?
Background The primary feature of the two main central disorders of hypersomnolence—narcolepsy and idiopathic hypersomnia (IH)—is excessive daytime sleepiness, defined in the International Classification of Sleep Disorders, third edition,... read >
The Cost of Prescription Medications Has Risen by More Than 20% in the Past Year
See our Disability and Insurance web page for updated content—to learn more about finding insurance and filing claims successfully in order to access the treatments you need at an affordable price or set up a disability income stream if you can no... read >
Summary of Rationale Behind and Research Studies into L-carnitine as a Treatment for Narcolepsy
Background In this 2013 study published in PLoS One, the researchers Miyagawa et al hypothesized that L-carnitine supplementation might help improve narcolepsy symptoms by increasing β-fatty-acid oxidation. Fatty acids are a major energy source for... read >
2015 HF Year in Review
“Overwhelmed!” “Excited!” “Incredibly grateful!”at the Hypersomnia Foundation, we are thrilled beyond belief following our “Giving Tuesday” campaign that expanded beyond a single day and actually ran through the end of 2015. Your... read >
BUNIHPPS Study Final Reminder
This is your final reminder email about BUNIHPPS- a survey research study for patients with narcolepsy or idiopathic hypersomnia. Dr. William DeBassio and Sara Kowalczyk are the study investigators of the Boston University Narcolepsy and Idiopathic... read >
HF Welcomes Several New Board Members
The Board of Directors of the Hypersomnia Foundation is pleased to introduce three new board members to the Board of Directors, Scientific Advisory Board, and Medical Advisory Board. Diane Powell and to announce the appointment of two new members of the... read >
EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy
On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In... read >
Crash Course: Public School Accommodations for Children with Hypersomnia – Part 4
This is the last in a series of four articles explaining how to navigate the public school system for accommodations under a 504 plan. You can read the other parts here: part 1, part 2, and part 3. By Kate Pece, MEd A K-12 Idiopathic Hypersomnia Fact... read >
The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway
ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults. More than 20 study sites throughout the United States are... read >
Public School Accommodations for Children with Hypersomnia: Part 3
Crash Course: Public School Accommodations for Children with Hypersomnia By Kate Pece, MEd In this series of four articles, you will learn how to navigate the public school system for accommodations under a 504 plan. You can read the other parts... read >